# 002010 · claims · run 39533973341

Model `claude-opus-5-5`, Claude Code 2.1.284, permission mode `default`. Tools: `Task`, `Bash`, `DesignSync`, `Edit`, `EnterWorktree`, `ExitWorktree`, `Glob`, `Grep`, `ListAgents`, `NotebookEdit`, `Read`, `ReportFindings`, `SendMessage`, `Skill`, `TaskCreate`, `TaskGet`, `TaskList`, `TaskStop`, `TaskUpdate`, `ToolSearch`, `WebFetch`, `WebSearch`, `Write`.

**Agent calls Bash**

```bash
cat docs/protocol.md | sed -n '/Reader/,$p' | head -300; ls claims/001453 paper/ claims/002010 2>&1
```

Result: not kept, because it reads the paper's text.

**Agent calls Bash**

```bash
awk '/^## Reader/{f=1} /^## Author/{f=0} f' docs/protocol.md
```

```
## Reader

### 1. Get the paper

The workflow puts the paper's full text, and its PDF where there is one, under
`paper/`: the main text, the Methods, and the supplement. Read the text; open
the PDF only to read a figure or a table the text garbles. If the full text is
not there, or lacks the Methods or a supplement the results rest on, stop:
write no claims, and end with a report that names what is missing, so that it
can be supplied. Never write claims from the abstract. Do not copy figures.
Do not look at the dataset's data: its title and description on the archive
are enough to know which paper and which experiments it is meant to hold.

### 2. Read the paper's code

Read the code the paper links to before writing criteria. Say what it holds,
and record the repository and commit read. Where the Methods leave a choice
open and the code settles it, follow the code and say so. Where they disagree,
follow the Methods for the main result and name the code's choice as a
variant. When more sources disagree (the Methods, the analysis code, the
[... 114 more lines not kept]
```

**Agent calls Bash**

```bash
cat claims/001453/*.yaml | head -200; wc -l paper/*.txt; head -30 paper/*.txt
```

Result: not kept, because it reads the paper's text.

**Agent calls Bash**

```bash
sed -n 30,408p paper/*.txt
```

Result: not kept, because it reads the paper's text.

**Agent calls Read**

```json
{
 "file_path": "/home/runner/.claude/projects/-home-runner-work-reproduction-registry-reproduction-registry/316fc6ab-2c0a-4492-8699-82477390e626/tool-results/bgb1sx2y1.txt"
}
```

```
1	
2	Finally, we probed the localization principle, a classical concept in neuroscience of a spatial organization into functional compartments ( 8 ), which remains controversial for the mRF. We dispersed small hM3Dq transfection sites across the mRF, and grouped and mapped these based upon type and magnitude of walking style. This functional assay contrasts with standard approaches that employ standardized anatomical boundaries as the basis for analyses. Such boundaries are notoriously ambiguous in the mRF and depend upon morphology ( 25 , 40 ) to which functionally, molecularly or neurochemically distinct entities may not adhere ( 18 , 25 , 41 , 42 ). This design uncovered spatially restricted mRF hotspots that differentially modulated walking style, the circuit specificity of which we further verified.
3	
4	## Results
5	
6	## Chemogenetic mRF modulation elicited different walking styles
7	
8	To determine whether enhanced activation of inhibitory, excitatory or serotonergic mRF neurons induced different walking styles, we injected small volumes (median 35nl) of AAV8-DIO-hM3Dq-mCherry uni- or bilaterally into subregions of the mRF of VGaT-ires-cre, VGluT2-ires-cre and SerT-cre mice ( Fig. 2a ). Following transfection, we video-captured self-paced over-ground walking under baseline (saline i.p.) and activation conditions (0.3mg/kg CNO i.p; Figure 2-Figure supplement 1; Table S1 for dose and time titration) using a walkway that incites mice to walk rather than run ( 36 , 38 ).
9	
10	Chemogenetic activation of VGaT, VGluT2 or SerT mRF neurons elicited contrasting walking styles. a: Small sites with inhibitory (VGaT), excitatory (VGluT2) or serotonergic (SerT) brainstem neurons were selectively transfected with hM3Dq, at the group level covering the entire region of interest. Walking gait, motor behavior and electrophysiological data were collected in control (saline) and activation (CNO) conditions. b: Average stride velocity decreased following hM3Dq activation in exp
[... 164 more lines not kept]
```

**Agent calls Read**

```json
{
 "file_path": "/home/runner/.claude/projects/-home-runner-work-reproduction-registry-reproduction-registry/316fc6ab-2c0a-4492-8699-82477390e626/tool-results/bgb1sx2y1.txt",
 "offset": 175,
 "limit": 206
}
```

```
175	
176	## Materials and Methods
177	
178	## Ethics statement
179	
180	Handling and housing of animals, surgical procedures, post-operative monitoring, behavioral tests and euthanasia were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health at the animal research facility of the Center for Life Sciences. The Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center reviewed and approved the experimental protocols (#069-2022). Survival surgeries were performed under isoflurane anesthesia and under aseptic conditions. The analgesic agent Meloxicam was given prior to surgery and on the first postoperative day.
181	
182	## Viral vectors and tracers
183	
184	All viral vectors have been described and used before:pAAV8-hSyn-DIO-hM3D(Gq)-mCherry (Bryan Roth ( 45 ); UNC Vector core; RRID: Addgene_44361), AAV2/5-hSyn-hChR2(H134R)-EYFP or AAV2/5-hSyn-hChR2(H134R)-mCherry(1.3×10 12 ; Stanford Gene Vector and Virus Core; K. Deisseroth), AAV8-EF1a-DIO-synaptophysin-mCherry (MGH Vector core; gift by Dr. B. Lowell, BIDMC). Cholera Toxin subunit B (CTb; List Biological) was used as conventional tracer. For AAV injections into the brainstem volumes ranged from 5-100nl (median 35nl). For spinal cord and muscle CTb injections, volumes ranged from 25-150nl (median 100nl; 1% in distilled water), and 0.5-1µl (median 0.8µl; 0.1% in distilled water), respectively.
185	
186	## DREADD activation experiments
187	
188	## Animals
189	
190	To study effects of chemogenetic activation of excitatory, inhibitory and serotonergic neurons in the medial pontomedullary reticular formation (mRF) on walking we used 35 male VGaT-ires-cre knock-in mice and 10 WT litter mate controls, C57Bl6/J background; RRID: IMSR_JAX#: 016962 ( 34 ), 46 VGluT2-ires-cre and 7 WT litter mate controls, C57Bl6/J background; RRID: IMSR_JAX#: 016963 ( 34 ), and 18 transgenic SERT-cre mice and 15 litter mate controls: (Tg(Slc6a4-c
[... 190 more lines not kept]
```

**Agent calls Bash**

```bash
grep -rl "002010" --include=*.md --include=*.yaml --include=*.json . 2>/dev/null | head; ls; ls claims | head -50; grep -rn -i "supplement.*missing\|missing.*supplement\|Table S" docs/*.md | head -20
```

```
./targets/dandisets.json
./papers/manifest.yaml
LICENSE
README.md
attempts
bunfig.toml
claims
docs
entries
node_modules
package-lock.json
package.json
paper
papers
pnpm-lock.yaml
questions
schemas
scripts
targets
tests
[... 66 more lines not kept]
```

**Agent calls Bash**

```bash
grep -n -B3 -A25 "002010" papers/manifest.yaml; python3 -c "
import json;d=json.load(open('targets/dandisets.json'))
import sys
s=json.dumps(d)
i=s.find('002010');print(s[i-200:i+3000])"; sed -n 4725,4760p docs/pilot-notes.md; sed -n 85,110p docs/pipeline.md
```

```
1926-    source: europe_pmc+crossref (paper-text-fetcher)
1927-    pdf: false
1928-    supplements: 0
1929:  '002010':
1930-  - doi: 10.1101/2023.04.19.537568
1931-    status: stored
1932-    version: preprint, version 1
1933-    source: bioRxiv JATS XML (api.biorxiv.org)
1934-    pdf: false
1935-    supplements: 0
1936-  '002013':
1937-  - doi: 10.1021/acschemneuro.5c00071
1938-    status: stored
1939-    version: as served by europe_pmc
1940-    source: europe_pmc+crossref (paper-text-fetcher)
1941-    pdf: false
1942-    supplements: 0
1943-  '002014':
1944-  - doi: 10.1016/j.jneumeth.2025.110467
1945-    status: stored
[... 70 more lines not kept]
```

**Agent**

I wrote no claims. The paper's text is here, but the supplement that its statistical results rest on is missing, so under the Reader section, step 1, I stopped.

**Text read:** `paper/10.1101-2023.04.19.537568.txt`, the bioRxiv preprint (version 1, from the JATS XML). It has the main text, the Methods, the figure legends and the figure supplement legends. There is no PDF and no supplement file (`papers/manifest.yaml` lists `supplements: 0`).

**What is missing:**
1. **Supplementary Tables S1 to S18.** The paper puts the statistical results of almost every finding in these tables. The text and legends only point to them ("Table S3 for statistical details", and so on). Examples:
   - Fig. 2b stride-velocity t-tests (S2).
   - Slomo, shuffle and fast signature F-tests (S3, S8, S12).
   - EMG tests (S4, S10, S13) and the Z-score correlations (S5).
   - Laterality tests (S7, S11) and motor tests (S6, S9, S14).
   - Bouton counts and sensory tests (S15 to S17) and optogenetics (S18).
   - Dose and time titration (S1).

   Without them, no claim could have the paper's statistics or reported values, beyond a few numbers in the text (such as p 0.016 for lamina III boutons).
2. **The Z-score equation in the Methods** (section "a) Group definition"). The text breaks off at "Z-scores of the change in gait metrics were then calculated as follows:" and the equation is gone, probably an image that the XML extraction dropped. Every subgroup in the paper (slomo, shuffle, fast, and their opposites) is defined by Z_SwT or Z_StrV thresholds, so no criterion could fix how mice are grouped.
3. **Figure 7-Figure supplement 3:** the legend is cut off after its title.

**To proceed:** someone needs to add the bioRxiv supplementary file with Tables S1 to S18, and the preprint PDF so the Z-score equation can be read. A reader run can then write the claims. Because I stopped, I did not read the linked code (the two SourceForge projects, gait-analysis-gui and gait-emg-step-trigger).

**Counts:** 0 claims, so 0 with quotes, statistics or criteria. No open details or readings were recorded. Nothing was written under `claims/002010/`.

## End of run

9 turns, 1 minutes, result: success.
